Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Epilepsia Partialis Continua

  • Author: Claude G Wasterlain, MD, MSc; Chief Editor: Selim R Benbadis, MD  more...
 
Updated: Nov 30, 2015
 

Overview

Introduction

On January 21, 1894, Kojewnikoff first presented his description of a unique type of prolonged focal seizure, which he named epilepsia partialis continua, at a meeting of the Moscow Neurological and Psychiatric Society.[1] Since then, this name has been ascribed to various nosological entities, with the condition being described as a variation of jacksonian epilepsy, as a jacksonian status epilepticus, as myoclonus epilepsy, as an extrapyramidal syndrome, or as continuous, localized myoclonia.

Epilepsia partialis continua can be considered the status epilepticus equivalent of simple partial motor seizures. It manifests itself as focal motor clonic seizures without jacksonian march, seizures remain localized to the part of the body in which they originate, and motor activity is often persistent, lasting for at least 60 minutes and often for hours, days, weeks, or even longer. Consciousness usually is preserved, since the thalamus is spared and seizures remain unilateral in most cases, but postictal weakness is frequently evident.[2, 3]

In the vast majority of cases, the seizures are of cortical origin; however, subcortical mechanisms also have been proposed.[4] Epilepsia partialis continua can be an expression of a stable neurologic lesion or a progressive disease, such as Rasmussen syndrome.[5] Antiepileptic drugs, with a few notable exceptions, do not seem to significantly alter the course of this condition.[6] While the localized nature of epilepsia partialis continua is one of its most striking features, occasional spread is seen in otherwise typical cases, and using spread as an exclusion criterion is not warranted.

Historical perspective and definition

Kojewnikoff (1895),[7] Bruns (1895),[8] Orlovskij (1896),[9] and Choroschko (1907)[10] all reported a similar condition characterized by intermittent muscular twitching of a body part while consciousness is unaffected. Kojewnikoff described 4 cases in which the patient experienced seizures, consisting of constant jerking movements of high frequency that were resistant to treatment and involving only one part of the body.[1] He recognized that this type of seizure could have many causes, such as a tumor, an abscess, syphilis, edema, embolism, or localized encephalitis. He postulated, without postmortem studies, that the seizures resulted from focal cortical encephalitis and localized the inflammation of the brain in the motor pathway.[1, 7, 11] This original description of epilepsia partialis continua has been extensively discussed,[12, 13] and its incidence in Russian spring-summer encephalitis has been recently reviewed.[14]

From 1904-1907, Speilmeyer and Mills reported,[15, 16] under the name of jacksonian epilepsy, cases in which epilepsia partialis continua may have been present. Since then, a number of clinical and pathological studies have further defined the syndrome, its location, and its etiology.[17]

In 1966, Juul-Jensen and Denny-Brown defined epilepsia partialis continua as “clonic muscular twitching repeated at fairly regular short intervals in one part of the body for a period of days or weeks.”[4] They also differentiated it from myoclonus by characterizing the latter as “more rapid, lasting less than half a second, involving a variable number of muscles... at irregular intervals,” but recognized the existence of transition forms, which are difficult to classify.

In 1977, Thomas et al defined epilepsia partialis continua as “a partial somatomotor SE... for a minimum of one hour and recurring at intervals of no more than 10 seconds.”[17] They carefully described the features of epilepsia partialis continua in 32 patients. Epilepsia partialis continua had a sudden onset in 17 of 25 patients; its durations varied from 4 hours to 18 years. Movement frequency was 0.5-10 Hz, and the duration varied from 25-600 milliseconds, with twitches often recurring every 2-3 seconds. Spike or sharp wave on scalp EEG preceded the movement in 9 of 12 patients, and all 5 corticographies revealed a cortical origin. Seventeen of 25 patients had a poor response or no response to anticonvulsants, and 6 of the 7 responders had acute brain lesions so that the therapeutic success could have been coincidental. Interestingly, cortical excision failed to stop the seizures in 4 of 5 patients.

In 1983, Gastaut defined epilepsia partialis continua as a subtype of somatomotor simple partial status epilepticus, which was itself a form of elementary partial status epilepticus; this definition made the point that there are as many types of status epilepticus as there are types of seizures.[18] Several subsequent reviews have used this definition.[6]

In 1985, Obeso et al defined epilepsia partialis continua as spontaneous regular or irregular clonic muscle twitching of cerebral cortical origin, confined to one part of the body and continuing for a period of hours, days, or even weeks.[19] The addition of “irregular” to the description recognizes the fact that the interval between motor twitches can vary but, in the author’s view, makes a clear distinction from myoclonus impossible.

Cockerell et al (1996)[20] and Shorvon (1994)[21] defined epilepsia partialis continua as “a syndrome of continuous focal jerking of a body part occurring over hours, days, or even years” and restricted the definition to jerks of cortical origin; they proposed the name “myoclonica continua” for jerks of subcortical origin. While this distinction is attractive in principle, in practice localizing the exact origin of the seizures is often difficult, and clinical activity indistinguishable from epilepsia partialis continua has been associated with subcortical pathology (eg, multiple sclerosis).

Wilson and Winkelman, (1924)[11] Hess and Sethi, (1990)[22] and Biraben and Chauvel (1998)[23] restricted epilepsia partialis continua to local and elementary motor signs, regardless of whether it was associated with spreading seizures at times.

In current practice, epilepsia partialis continua is defined as a form of partial status epilepticus with simple motor manifestations that are maintained for over 1 hour, with clonic activity restricted to one body part and recurring at fairly regular intervals. The following modifying factors apply:

  • Motor activity often is modified by sensory stimuli
  • Frequency is usually 0.1-6 Hz
  • Epilepsia partialis continua can continue for long periods (sometimes years) without spreading, although spread can occur at times
  • Epilepsia partialis continua often is associated with postictal or interictal weakness

Clonic activity in epilepsia partialis continua can involve any muscle group and is most common in the upper extremities. Although it is typically invariant and remains localized to a single muscle group in most patients, it may be accompanied by jacksonian spread of the seizure, which may even lead to a complex partial or secondarily generalized seizure. This syndrome also may be accompanied by other neurological and psychopathological symptoms.

Bancaud classification

Bancaud et al (1982)[3] classified epilepsia partialis continua into 2 groups. Both entities start with similar seizures, but type 2 proves to be intractable and progressive. See the Table below.

Table. Bancaud Classification (Open Table in a new window)

Type 1 ( Classic) Type 2 (Rasmussen)
Rolandic fixed lesion Normal developmental and history until seizure onset
Neurological deficit Preceding partial motor
Preceding partial motor seizures Following myoclonic jerks
Following myoclonic jerks Abnormal EEG background with focal and diffuse paroxysmal abnormalities
Focal abnormalities on EEG Progressive course
Nonprogressive course Intractable epilepsy
Surgery usually effective  

Bancaud divided the clinical course of type 2 into 3 stages. The first stage features only simple partial motor or complex partial seizures, but epilepsia partialis continua may occur. In the second stage, epilepsia partialis continua is seen in the setting of progressive neurologic deficit and mental deterioration. The third stage is characterized by arrest of deterioration and decrease or disappearance of seizures.

Go to Epilepsy and Seizures, Status Epilepticus, and Partial Epilepsies for an overview of these topics.

Patient education

For patient information, see the Brain and Nervous System Center, as well as Epilepsy.

Next

Epidemiology

Since the first description by Kojewnikoff, a number of isolated case reports and small case series have elucidated this syndrome further. However, few epidemiologic studies have been performed. Cockerell et al (1996) estimated the prevalence of epilepsia partialis continua at less than 1 case per million population, based on 36 cases reported in the United Kingdom over a 1-year period, 10 of the cases being new.[20]

The incidence of epilepsia partialis continua is slightly higher in males than in females.[4, 17, 20] In a retrospective review by Sinha and Satishchandra (2007) of 76 patients with epilepsia partialis continua at a tertiary care center in South India over the course of 14 years, the investigators found a male-to-female ratio of 46:30, a mean age of 30.2 ±23.4 years, and a median age of 26 years.[24]

Previous
Next

Pathophysiology

Historical studies

In 1895, Kojewnikow postulated that myoclonus and seizures arose from the cerebral cortex in association with localized encephalitis. His brilliant insight contrasted with the then current view that somewhat clinical entities, such as Friedreich paramyoclonus multiplex and familial progressive myoclonic epilepsy of Unverricht, resulted from hyperexcitability of the anterior horn cells.[25] and it has been proven right in the overwhelming majority of cases of epilepsia partialis continua.

In 1922, Souques considered that dysfunction of the motor cortex was the cause of focal motor seizures, but that localized myoclonias must be of subcortical origin.[26] The first EEG study of myoclonus with epilepsy was performed by Grinker et al.[27] They demonstrated a temporal correlation between frontal polyspikes and waves and myoclonic jerks at the periphery.

In 1947, Dawson showed that the motor jerks were preceded by fast (30 Hz) discharges in the contralateral motor cortex.[28] The EEG discharge had an exclusive waveform, beginning with a positive wave immediately followed by negative shift on which a train of spikes was superimposed. When neither the negative shift nor the spike train occurred, no myoclonic jerking was observed.

Dawson also recorded scalp somatosensory evoked potentials (SSEPs) for the first time in response to the electrical stimulation of the nerve trunk. Their maximal amplitude was located near the midline for the lower limb, and 6-8 cm more lateral to the upper limb. He concluded that these evoked potentials represented exaggerated responses of the underlying cortex to peripheral stimuli, and that hyperexcitability of motor cortex, rather than increase of afferent volley to the primary somatosensory cortex via subcortical mechanisms, would account for the precentral site of projection.

In 1954, Kugelberg and Wieden reported a case of epilepsia partialis continua and remarked on the constant relationship with a 27-34 millisecond latency, between myoclonic jerking of the right foot and the focal EEG spikes in the central areas, maximal on the left side near the midline.[29] In this patient, the motor cortex was excised with complete remission of the seizures.

Physiology

The unequivocal cortical origin of epilepsia partialis continua appears to be substantiated in humans by clinical, electrophysiologic, and neurosurgical evidence. In addition, an epileptogenic lesion of the central neocortex can mimic this phenomenon in monkeys.[30]

The neocortex is endowed with powerful lateral inhibition, which probably is designed to keep responses precisely localized. This may be the reason that epilepsia partialis continua can go on for a long period while remaining precisely localized to a small group of muscles and a small cortical domain. Since surround inhibition may limit seizure spread more effectively in the motor neocortex than in any other area because of the tight afferent-efferent relationships, which support the activation of long-loop reflexes, epilepsia partialis continua may be a unique expression of cortical organization.[31, 30] However, note that seizures sometimes can be driven from distant, or even subcortical, sites.[32]

By contrast, the limbic system, which is involved heavily in processes such as memory and emotion, is designed to spread excitation widely and to modulate excitability in many brain regions. Perhaps, as a result of this organization, seizures of limbic origin often spread widely and rapidly.

Metabolism

The epilepsia partialis continua focus (1) is hypermetabolic, as shown by 2-deoxyglucose positron emission tomography (PET) scanning; (2) is hyperactive, as seen as by magnetoencephalogram (MEG) studies; and (3) shows increased blood flow in single-photon emission computed tomography (SPECT) scan studies.[23]

Synaptic mechanisms

Synaptic mechanisms have been studied only in self-sustaining status epilepticus, not in epilepsia partialis continua. The author now suspects that self-sustaining status epilepticus is initiated by failure of GABAergic inhibition but is maintained by widespread potentiation of excitatory (especially N -methyl-D-aspartate [NMDA]) synapses; therefore, established self-sustaining status epilepticus becomes resistant to all agents except NMDA antagonists.[33] The authors speculate on a similar mechanism in epilepsia partialis continua, in which the focus would be characterized by long-term potentiation of glutamate receptors and desensitization of GABA receptors, while GABAergic inhibition would be preserved in the surround.

Previous
Next

Clinical Presentation

Clonic activity can involve any muscle group and is most common in the upper extremities. Although it is typically invariant and remains localized to a single muscle group in most patients, it may be accompanied by jacksonian spread of the seizure, which may even lead to a complex partial or secondarily generalized seizure. About 60% of patients have other types of seizures besides epilepsia partialis continua.[20] These data are also illustrated in a study by Kravljanac et al,[34] where all 51 patients in the study experienced one or more types of epileptic seizures besides epilepsia partialis continua. This syndrome also may be accompanied by other neurological and psychopathological symptoms.

The topographic distribution of seizures from one study of epilepsia partialis continua is as follows:

  • Motor deficit (56%) - Tetraparesis (4%), hemiparesis (23.3%), monoparesis (13.3%), oculomotor paresis (0.7%), facial paresis (10%), hypoglossal paresis (1.9%), soft palate paresis (0-3%)
  • Sensory deficit (21%) - Hemihypoesthesia and hemianesthesia (9.7%), monohypoesthesia and monoanesthesia (4.4%), deep sensation (3.6%), stereognosis (3.3%)
  • Anisocoria (1%)
  • Conjugate deviation of eyes (1%)
  • Homonymous hemianopsia (5%)
  • Aphasia (14%) - Motor (8.3%), sensory (2.5%), amnestic (2.6%)
  • Apraxia (1%)
  • Alexia (2%)

Neurological symptoms distribution in a study of epilepsia partialis continua (N=246) is as follows:

  • Head (n=24) - Mouth (9), face (11), periorbital muscle (2), soft palate (2), hypersalivation (1)
  • Upper extremities (n=60) - Thumb (4), finger (6), hand (24), arm (26)
  • Trunk (n=8) - Shoulder (4), breast (1), abdomen (3)
  • Lower extremities (n=22) - Big toe (2), leg (10), foot (10)

Neuropsychological symptoms distribution in a study of epilepsia partialis continua is as follows:

  • Disturbance of consciousness (36%) - Somnolence (19%), stupor (3%), coma (14%)
  • State of confusion (15%)
  • Disorientation (10%)
  • Labile affect (5%)
  • Stupor (5%)
  • Dementia (15%)
  • Others (14%)

Clinical neurophysiology

Neurologic evaluation is essential in view of the variety of etiologies and associated illnesses in patients with epilepsia partialis continua.

In general, electroencephalography has not been successful in determining the origin of epilepsia partialis continua. In Rasmussen encephalitis, the EEG often shows significant lateralized, slow-wave activity, and it may give evidence of other seizure types or projected abnormalities suggestive of widespread, but lateralized, disease. Frequently, lateralized, asymmetrical background slowing is noted.

Similar findings also can be seen with other etiologies, such as glial tumors. In the case of focal, nonprogressive pathologies, such as chronic stroke, the background is rarely as abnormal or asymmetrical. This point may help in differentiating a focal, nonprogressive pathology from structural diseases with a coexistent metabolic encephalopathy, in which the background is often diffusely abnormal.

Evoked-potential techniques, especially somatosensory evoked potentials (SSEPs), have been used to examine the physiologic mechanisms and anatomical locations of epilepsia partialis continua.[6] Giant SSEPs are seen often and point to cortical hyperexcitability, which may be an essential mechanism of epilepsia partialis continua.

Previous
Next

Causes

Clinical and pathologic studies have identified various presumed causes of epilepsia partialis continua. This long list reflects the diverse nature of the pathologic processes that cause focal neocortical seizures. Nothing about these processes is specific, and the unique clinical features of epilepsia partialis continua are likely to reflect its anatomic location rather than its etiology.

In recent years, autoimmune processes associated with Rasmussen encephalitis have received considerable attention.[35, 36]

Cerebral neoplasia–related causes are as follows:

  • Metastasis
  • Astrocytoma
  • Oligodendroglioma
  • Carcinomatosis cerebri
  • Hemangioma
  • Lymphoma
  • Meningioma

Cortical dysplasia–related causes are as follows:

  • Conical dysplasia
  • Hemimegalencephaly
  • Tuberous sclerosis
  • Linear sebaceous nevus syndrome
  • Sturge-Weber syndrome

Traumatic lesion–related causes are as follows:

  • Acute head trauma
  • Posttraumatic cyst
  • Subdural hematoma
  • Intracerebral hematoma
  • Epidural hematoma

Drug-induced causes are as follows:

  • Penicillin
  • Azlocillin
  • Cefotaxime
  • Metrizamide

Metabolic causes are as follows:

  • Diabetic ketoacidosis
  • Nonketotic hyperglycemia
  • Hepatic encephalopathy
  • Uremic encephalopathy
  • Hyponatremia

Infectious or parasitic causes are as follows:

  • Abscess
  • Tuberculoma
  • Gumma
  • Russian spring-summer encephalitis
  • Subacute measles encephalitis
  • Human immunodeficiency virus
  • Progressive multifocal leukoencephalopathy
  • Creutzfeldt-Jakob disease
  • Viral encephalitis or meningoencephalitis
  • Cryptococcal meningitis
  • Anti-Hu–associated paraneoplasia
  • Cysticercosis
  • Granulomatous diseases
  • Pertussis infection

Vascular lesion–related causes are as follows:

  • Arteriosclerotic cerebrovascular disease
  • Embolic or postthrombotic ischemic infarction
  • Cortical venous thrombosis
  • Cerebral hemorrhage
  • Systemic lupus erythematosus
  • Sjögren syndrome
  • Arteriovenous malformation
  • Carotid hypoplasia

Autoimmune causes are as follows:

  • Rasmussen chronic encephalitis
  • Multiple sclerosis
  • Anti-GluR3 or anti-NMDA-GluR-Epsilon 2 antibodies

Genetic causes are as follows:

  • Alpers disease
  • Kufs disease
  • Leigh syndrome and cytochrome C oxidase deficiency
  • Nicotinamide adenine dinucleotide (NADH) coenzyme Q reductase deficiency
  • Mitochondrial cytopathies including mitochondrial encephalopathy with lactic acidosis and stroke (MELAS)
Previous
Next

PET SPECT and MRI Scans

Positron emission tomography (PET) scanning and single-photon-emission computed tomography (SPECT) scanning are emerging as useful research tools in the evaluation of the metabolic effects of epilepsia partialis continua, especially when computed tomography (CT) and magnetic resonance imaging (MRI) findings are normal or may show a lesion.

PET scan studies are also likely to enhance understanding of the biochemical and metabolic features associated with the abnormal physiology, and, consequently, they may provide significant information not only for the diagnosis of epilepsia partialis continua but also for its treatment.[37] Burneo (2006) reported that ictal SPECT has also been useful in the presurgical evaluation of Rasmussen encephalitis.[38]

MRI can point to the structural lesion of the cortex and/or white matter, and it can follow the progression of atrophy in Bancaud type 2 epilepsia partialis continua.[23]

SPECT-MRI fusion has been reported by Matthews to have been successfully used to identify epileptic focus in a patient with epilepsia partialis continua.[39]

Previous
Next

Prognosis

The long-term prognosis of epilepsia partialis continua depends on its underlying cause. The early onset of epilepsia partialis continua in a child is often, but not always, a manifestation of neurodegenerative disease or Rasmussen encephalitis, and these conditions often are associated with progressive neurologic decline. Numerous studies have suggested that epilepsia partialis continua is not in the infectious process but has autoimmune and inflammatory components. Cytokines, such as interleukin 1B and tumor necrosis factor-α, may play a role in epilepsia partialis continua as they alter neuronal excitability and contribute to neuronal cell loss, astrogliosis, and blood-brain barrier damage.[40, 41, 42]

Kravljanac et al (2013) conducted a cohort study of 51 children with epilepsia partialis continua and recorded neurological consequences in 64.7% and fatal outcomes in 15.7% of the patients.[34] The study found that the strongest predictors for both neurological consequences and lethal outcome were EEG characteristics, the application of intensive therapy, and epilepsia partialis continua onset in the late phase of disease. A better prognosis was reported in patients with epilepsia partialis continua type I than with Rasmussen encephalitis (epilepsia partialis continua type II).[43]

In patients with adult-onset epilepsia partialis continua, the underlying cause can be fixed (eg, cortical dysplasia, stable arteriovenous malformation), self-limiting (eg, trauma, stroke), or progressive (eg, tumor, carcinomatous meningitis); the prognosis depends on the underlying pathology.

Kim et al (2012) reported a patient who developed alien hand syndrome after experiencing epilepsia partialis continua.[44] Brain MRI and fluorodeoxyglucose (FDG) PET studies found extensive hypometabolism over lesions in epileptogenic zones. Studies by Weitemeyer et al (2005) and Van Paesschen et al (2007) showed high concordance rates between hypometabolism on interictal PET and frontal lobe epilepsy.[45, 46] Thinning of the corpus callosum was noted on MRI. The investigators suggest that epilepsia partialis continua may have been the cause of the structural damage to the patient’s corpus callosum resulting in the neurological deficits. Hence, Kim et al, (2012) recommend that physicians consider aggressive and prompt management for certain etiologies of epilepsia partialis continua.[44]

Previous
Next

Pharmacologic Treatment

Treatment should focus on the underlying condition. Antiepileptic drugs (AEDs) are usually tried to prevent the spread of seizures, but with a few notable exceptions, they are often unsuccessful in altering the course of epilepsia partialis continua. Polytherapy is often complicated by adverse effects and drug interactions.[20] Immunosuppression may have a place in the treatment of Rasmussen encephalitis. Hemispherectomy has been shown to prevent the progression of Rasmussen encephalitis in selected cases, at the cost of sometimes aggravating hemiparesis and other deficits.[47, 48]

AEDs

Benzodiazepines may provide temporary relief.[49] Phenytoin or phenobarbital may be more effective than carbamazepine or valproate.[23] Echenne (1997) and Bhidayasiri et al (2012) reported success with felbamate in patients who responded poorly to other AEDs.[50, 51] Topiramate may be successful in epilepsia partialis continua with dysontogenetic etiologies.[52] Nimodipine has been administered successfully in 2 cases of epilepsia partialis continua following an acute cerebral event.[53]

Control of epilepsia partialis continua may be achieved by a combination of intravenously administered AEDs, including diazepam, pentothal sodium, and valproate.[43] A case report by Eggers et al (2009) illustrates a patient who sustained immediate epilepsia partialis continua relief after receiving an intravenous bolus of levetiracetam, even though the patient presented with epilepsia partialis continua while taking levetiracetam orally.[54] This study supports the view that supratherapeutic serum concentrations of AEDs may help in some patients.[55]

Immunosuppression

Oral corticosteroid therapy and immunosuppression may be of some benefit in rare cases.[56] Recent evidence supports a correlation between Rasmussen encephalitis and autoimmune processes.[57, 58, 59] Some Rasmussen patients have antibodies to the glutamate receptor subunit, GluR3.[57] or to NMDA receptors.[60]

Natalizumab, rituximab, tacrolimus and intravenous immunoglobulin (IVIG) have been reported to be effective in Rasmussen encephalitis.[61, 62, 63, 64] Barontini et al (1994) reported the use of gamma globulins, but few lasting benefits have been reported to date.[65] Plasma exchange has been reported to have improved epilepsia partialis continua significantly in a few Rasmussen patients.[66]

Other pharmacotherapy

Because cytomegalovirus has been implicated in the pathogenesis of Rasmussen syndrome, McLachlan et al (1996) used ganciclovir and reported that epilepsia partialis continua was controlled in one patient with this syndrome.[67] Intraventricular interferon alfa was reported to have completely controlled epilepsia partialis continua in another patient with Rasmussen encephalitis.[68]

Adverse effects of drugs should also be considered in the differential diagnosis of epilepsia partialis continua to facilitate rapid diagnosis and drug discontinuation. Treatment with medications such as penicillin, azlocillin, and cefpodoxime have been reported to cause partial motor seizures.[69, 70] A case study performed by Aberastury et al (2010) reports a patient experiencing epilepsia partialis continua with positive white matter lesions in cortical and subcortical regions on MRI after taking levamisole 1 g/wk for 2 weeks.[71] This patient had no prior family history of metabolic or neurologic diseases, nor did she have any medical conditions besides oral aphthous ulcers for which she was prescribed levamisole.

Previous
Next

Other Treatment Techniques

Neurosurgical approaches, such as multiple subpial transections,[72] may be used as a last resort. Hemispherectomy should be considered in cases of Rasmussen encephalitis.

Repetitive transcranial magnetic stimulation has been reported to have lasting success in anecdotal cases and may deserve further evaluation.[73, 74, 75] A study was conducted by Rotenberg et al (2009) that looked at 7 patients with epilepsia partialis continua of mixed etiologies and after treating the patients with repetitive transcranial magnetic stimulation over the seizure in either high frequency (20-100 Hz) bursts or prolonged low frequency (1 Hz) trains found that 3 of 7 patients experienced brief (20-30 min) pauses in seizures and 2 of 7 experienced a lasting (≥1 d) pause in their seizures.[76]

A case of successful treatment of facial myoclonus with botulinum toxin has been reported.[77]

Previous
 
Contributor Information and Disclosures
Author

Claude G Wasterlain, MD, MSc Chair, Department of Neurology, VA Greater Los Angeles Health Care System; Distinguished Professor and Vice-Chair, Department of Neurology, University of California, Los Angeles, David Geffen School of Medicine

Claude G Wasterlain, MD, MSc is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Federation for Medical Research, American Neurological Association, Royal Society of Medicine, Society for Neuroscience

Disclosure: Nothing to disclose.

Coauthor(s)

Leo L Chen, MD Consulting Staff, Department of Neurology, Kaiser-Permanente of Davis

Leo L Chen, MD is a member of the following medical societies: American Academy of Family Physicians, American Academy of Neurology, American Medical Association, American Medical Student Association/Foundation

Disclosure: Nothing to disclose.

Michael M Gezalian, MD Intern Resident Physician, Department of Neurology, Loma Linda University Medical Center

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Norberto Alvarez, MD Assistant Professor, Department of Neurology, Harvard Medical School; Consulting Staff, Department of Neurology, Boston Children's Hospital; Medical Director, Wrentham Developmental Center

Norberto Alvarez, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, Child Neurology Society

Disclosure: Nothing to disclose.

Chief Editor

Selim R Benbadis, MD Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Cyberonics; Eisai; Lundbeck; Sunovion; UCB; Upsher-Smith<br/>Serve(d) as a speaker or a member of a speakers bureau for: Cyberonics; Eisai; Glaxo Smith Kline; Lundbeck; Sunovion; UCB<br/>Received research grant from: Cyberonics; Lundbeck; Sepracor; Sunovion; UCB; Upsher-Smith.

Acknowledgements

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author Guillermo Estrada, MD to the development and writing of this article. Supported by the Research Service of the Veterans Health Administration and by grants NS13515 and NS059704 from NINDS.

References
  1. Vein AA, van Emde Boas W. Kozhevnikov epilepsy: the disease and its eponym. Epilepsia. 2011 Feb. 52(2):212-8. [Medline].

  2. Gastaut H. [Semeiology of myoclonus and analytic nosology of myoclonic syndromes]. Rev Neurol (Paris). 1968 Jul. 119(1):1-30. [Medline].

  3. Bancaud J, Bonis A, Trottier S, Talairach J, Dulac O. [Continuous partial epilepsy: syndrome and disease]. Rev Neurol (Paris). 1982. 138(11):803-14. [Medline].

  4. Juul-Jensen P, Denny-Brown D. Epilepsia partialis continua. Arch Neurol. 1966 Dec. 15(6):563-78. [Medline].

  5. Bancaud J, Bonis A, Talairach J, Bordas-Ferrer M, Buser P. [Kojewnikow syndrome and somato-motor attacks (clinical, E.E.G., E.M.G. and S.E.E.G. study)]. Encephale. 1970 Sep-Oct. 59(5):391-438. [Medline].

  6. Schomer DL. Focal status epilepticus and epilepsia partialis continua in adults and children. Epilepsia. 1993. 34 Suppl 1:S29-36. [Medline].

  7. Kojewnikoff AY. Eine besondere Form von corticaler Epilepsie. Neurologie Zentralblatt. 1895. 14:47–48.

  8. Bruns. Anastomische und klinische Demostrationen. Neurol ZentraIbI. 1895. 14:47-48.

  9. Orlovskij, S. B. Ein Fall von epilepsia partialis continua (russ.) Medskoe. Obozr. Sprimona 43. Neurol. Zbl. 1825. 526:891-892.

  10. Choroschko VK. Zur Differentialdiagnostik der Polyclonia epileptoides continua (Kozevnikov). Neurol Zbl. 1908. 27:279.

  11. Wilson G, Winkelman NW. Partial Continuous Epilepsy. Arch Neurol Psychiat. 1924. 11:530-42.

  12. Spiller WG Martin E. Epilepsia partialis continua occurring in cerebral syphilis. JAMA. 1908. 52:1921.

  13. Burr CW. Continnuous Clonic Spasm of the Left A (Epilepsia Continua) Caused by a Tumor of the brain. Amer J med Sci. 1915. 149:169.

  14. Mukhin KY, Mameniskiene R, Mironov MB, Kvaskova NE, Bobylova MY, Petrukhin AS. Epilepsia partialis continua in tick-borne Russian spring-summer encephalitis. Acta Neurol Scand. 2012 May. 125(5):345-52. [Medline].

  15. Spielmeyer W, CentrtraIbI F, Nervenh U. Zur Symptomatologie der Grosshirnencephalitis, speziell uber eine epileptische form dieser Erkrankung. Psychiat. 1904. 27:371-383.

  16. Mills, CK. Circumscribed haemorrhagic cortical encephalitis, with the report of a case in which the lesion was limited to the motor zone, the chief clinical manifestation Jacksonian epilepsy. Rev. Neurol. & Psychiat. 1907. 5:389.

  17. Thomas JE, Reagan TJ, Klass DW. Epilepsia partialis continua. A review of 32 cases. Arch Neurol. 1977 May. 34(5):266-75. [Medline].

  18. Gastaut H. Classification of status epilepticus. Delgado-Escueta AV, Wasterlain CG, Treimann DM, Porter RJ. Status Epilepticus. New York: Raven Press; 1983. 34: 15–35.

  19. Obeso JA, Rothwell JC, Marsden CD. The spectrum of cortical myoclonus. From focal reflex jerks to spontaneous motor epilepsy. Brain. 1985 Mar. 108 ( Pt 1):193-24. [Medline].

  20. Cockerell OC, Rothwell J, Thompson PD, Marsden CD, Shorvon SD. Clinical and physiological features of epilepsia partialis continua. Cases ascertained in the UK. Brain. 1996 Apr. 119 ( Pt 2):393-407. [Medline].

  21. Shorvon S. Status Epilepticus: Its Clinical Features and Treatment in Children and Adults. Cambridge: Cambridge University Press; 1994.

  22. Hess DC, Sethi KD. Epilepsia partialis continua in multiple sclerosis. Int J Neurosci. 1990 Jan. 50(1-2):109-11. [Medline].

  23. Biraben A, Chauvel P. Epilepsia partialis Continua. Engel J, Pedley TA. Epilepsy: A Comprehensive Textbook. Philadelphia: Lippincott-Raven Publishers; 1998. 2447-53.

  24. Sinha S, Satishchandra P. Epilepsia Partialis Continua over last 14 years: experience from a tertiary care center from south India. Epilepsy Res. 2007 Apr. 74(1):55-9. [Medline].

  25. Unverricht H. Die myoklonie. Leipzig: Franz Deuticke; 1891.

  26. Souques M.A. Dissociation des paroxysmes convulsifs et des secousses inter paroxystique dans I E.P.C. et interpretation de cette dissociation. Rev Neurol. 1922. 1:61-63.

  27. Grinker RR, Serota H SI. Myoclonic epilepsy. Arch Neurol Psychiatry. 1938. 40:968-980.

  28. Dawson GD. Cerebral Responses to Electrical Stimulation of Peripheral Nerve in man. J Neurol Neurosurg Psychiatry. 1947 Aug. 10(3):134-40. [Medline]. [Full Text].

  29. Kugelberg E, Widen L. Epilepsia partialis continua. Electroencephalogr Clin Neurophysiol. 1954 Aug. 6(3):503-6. [Medline].

  30. Lamarche M, Chauvel P. Movement epilepsy in the monkey with an experimental motor focus. Electroencephalogr Clin Neurophysiol Suppl. 1978. (34):323-8. [Medline].

  31. Chauvel P, Trottier S, Vignal JP, Bancaud J. Somatomotor seizures of frontal lobe origin. Adv Neurol. 1992. 57:185-232. [Medline].

  32. Rothwell JC, Obeso JA, Marsden CD. On the significance of giant somatosensory evoked potentials in cortical myoclonus. J Neurol Neurosurg Psychiatry. 1984 Jan. 47(1):33-42. [Medline].

  33. Mazarati AM, Wasterlain CG. Blockers of NMDA receptor restore paired-pulse inhibition in the rat dentate gyrus lesioned by perforant path stimulation. Neurosci Lett. 1997 Oct 3. 234(2-3):135-8. [Medline].

  34. Kravljanac R, Djuric M, Jovic N, Djordjevic M, Zamurovic D, Pekmezovic T. Etiology, clinical features and outcome of epilepsia partialis continua in cohort of 51 children. Epilepsy Res. 2013 Mar. 104(1-2):112-7. [Medline].

  35. Li Y, Uccelli A, Laxer KD, Jeong MC, Vinters HV, Tourtellotte WW. Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. J Immunol. 1997 Feb 1. 158(3):1428-37. [Medline].

  36. Greiner H, Leach JL, Lee KH, Krueger DA. Anti-NMDA receptor encephalitis presenting with imaging findings and clinical features mimicking Rasmussen syndrome. Seizure. 2011 Apr. 20(3):266-70. [Medline].

  37. Yoshida T, Tanaka M, Masuda T, Okamoto K, Hirai S. [Epilepsia partialis continua with an epileptic focus demonstrated by PET and unique MRI findings: report of a case]. Rinsho Shinkeigaku. 1995 Sep. 35(9):1021-4. [Medline].

  38. Burneo JG, Hamilton M, Vezina W, Parrent A. Utility of Ictal SPECT in the presurgical evaluation of Rasmussen's encephalitis. Can J Neurol Sci. 2006 Feb. 33(1):107-10. [Medline].

  39. Matthews R, Franceschi D, Xia W, Cabahug C, Schuman G, Bernstein R. Parietal lobe epileptic focus identified on SPECT-MRI fusion imaging in a case of epilepsia partialis continua. Clin Nucl Med. Dec 2006. 31(12):826-8.

  40. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia. 2005 Nov. 46(11):1724-43. [Medline].

  41. Specchio N, Fusco L, Claps D, Vigevano F. Epileptic encephalopathy in children possibly related to immune-mediated pathogenesis. Brain Dev. 2010 Jan. 32(1):51-6. [Medline].

  42. Nabbout R, Vezzani A, Dulac O, Chiron C. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol. 2011 Jan. 10(1):99-108. [Medline].

  43. Pandian JD, Thomas SV, Santoshkumar B, Radhakrishnan K, Sarma PS, Joseph S. Epilepsia partialis continua--a clinical and electroencephalography study. Seizure. 2002 Oct. 11(7):437-41. [Medline].

  44. Kim HY, Kim JY, Kim GU, Han HJ, Shin DI. Alien hand syndrome after epilepsia partialis continua: FDG PET and MRI studies. Epilepsy Behav. 2012 Jan. 23(1):71-3. [Medline].

  45. Weitemeyer LKC, Weckesser M, Matheja P, et al. The prognostic value of [18F] FDG-PET in nonrefractory epilepsy. Epilepsia. 2005. 46:2654-60.

  46. Van Paesschen W, Dupont P, Sunaert S, Goffin K, Van Laere K. The use of SPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol. 2007 Apr. 20(2):194-202. [Medline].

  47. Takahashi Y, Yamazaki E, Mine J, Kubota Y, Imai K, Mogami Y. Immunomodulatory therapy versus surgery for Rasmussen syndrome in early childhood. Brain Dev. 2013 Sep. 35(8):778-85. [Medline].

  48. De Bode S, Fritz S, Mathern GW. Cerebral hemishperectomy; sensory scores before and afterintensive mobility training. Brain Dev. 2012 Sep. 34(8):625-31.

  49. Mameniskiene R, Bast T, Bentes C, et al. Clinical course and variability of non-Rasmussen, nonstroke motor and sensory epilepsia partialis continua: a European survey and analysis of 65 cases. Epilepsia. 2011 Jun. 52(6):1168-76. [Medline].

  50. Echenne B, Rivier F, Roubertie A, et al. Successful felbamate treatment of epilepsia partialis continua in a case of hemimegalencephaly. Epilepsia. 1997. 38 Supplement 3:36.

  51. Bhidayasiri R, Theodore WH, Estrada G, Seedhom A, Wasterlain CG. Successful Felbamate treatment of Epilepsia partialis continua North African and Middle East. Epilepsy Journal. 2012. 1(2):11-13.

  52. Wolf P, Bentes CC, Canevini MP, et al. Non Rasmussen, nonvascular epilepsia partialis continua. Epilepsia. 2009. 50 (suppl 12):86-87.

  53. Brandt L, Saveland H, Ljunggren B, Andersson KE. Control of epilepsy partialis continuans with intravenous nimodipine. Report of two cases. J Neurosurg. 1988 Dec. 69(6):949-50. [Medline].

  54. Eggers C, Burghaus L, Fink GR, Dohmen C. Epilepsia partialis continua responsive to intravenous levetiracetam. Seizure. 2009 Dec. 18(10):716-8. [Medline].

  55. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?. Clin Pharmacokinet. 2006. 45(11):1061-75. [Medline].

  56. Walker M, Shorvon S. Treatment of status epilepticus and serial seizures. The Treatment of Epilepsia. Blackwell Science; 1996. 280-2.

  57. Rogers SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science. 1994 Jul 29. 265(5172):648-51. [Medline].

  58. Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005 Mar. 128(Pt 3):454-71. [Medline].

  59. Owens GC, Huynh MN, Chang JW, McArthur DL, Hickey MJ, Vinters HV. Differential expression of interferon-? and chemokine genes distinguishes Rasmussen encephalitis from cortical dysplasia and provides evidence for an early Th1 immune response. J Neuroinflammation. 2013. 10:56. [Medline].

  60. Takahashi Y, Mori H, Mishina M, Watanabe M, Kondo N, Shimomura J. Autoantibodies and cell-mediated autoimmunity to NMDA-type GluRepsilon2 in patients with Rasmussen's encephalitis and chronic progressive epilepsia partialis continua. Epilepsia. 2005. 46 Suppl 5:152-8. [Medline].

  61. Bien CG, Tiemeier H, Sassen R, Kuczaty S, Urbach H, von Lehe M. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia. 2013 Mar. 54(3):543-50. [Medline].

  62. Bittner S, Simon OJ, Gobel K, Bien CG, Meuth SG, Wiendl H. Rasmussen encephalitis treated with natalizumab. Neurology. 2013 Jul 23. 81(4):395-7. [Medline].

  63. Geya-Dayan K, Shorer Z, Menascu S, Linder I, Goldberg-Stern H, Heyman E, et al. Immunoglobulin treatment for severe childhood epilepsy. Pediatr Neurol. 2012 Jun. 46(6):375-81.

  64. Thilo B, Stingele R, Knudsen K, Boor R, Bien CG, Deuschl G. A case of Rasmussen encephalitis treated with rituximab. Nat Rev Neurol. 2009 Aug. 5(8):458-62. [Medline].

  65. Barontini F, Maurri S, Amantini A. "Epilepsia partialis continua" due to multifocal encephalitis: favourable outcome after immunoglobulin treatment. Ital J Neurol Sci. 1994 Apr. 15(3):157-61. [Medline].

  66. Weiss PF, Klink AJ, Friedman DF, Feudtner C. Pediatric therapeutic plasma exchange indications and patterns of use in US children's hospitals. J Clin Apher. 2012. 27(6):287-94. [Medline].

  67. McLachlan RS, Levin S, Blume WT. Treatment of Rasmussen's syndrome with ganciclovir. Neurology. 1996 Oct. 47(4):925-8. [Medline].

  68. Dabbagh O, Gascon G, Crowell J, Bamoggadam F. Intraventricular interferon-alpha stops seizures in Rasmussen's encephalitis: a case report. Epilepsia. 1997 Sep. 38(9):1045-9. [Medline].

  69. Shiozawa Z, Sasaki H, Ozaki Y, Nakanishi T, Huang YP. Epilepsia partialis continua following metrizamide cisternography. Ann Neurol. 1981 Oct. 10(4):400-1. [Medline].

  70. Wroe SJ, Ellershaw JE, Whittaker JA, Richens A. Focal motor status epilepticus following treatment with azlocillin and cefotaxime. Med Toxicol. 1987 May-Jun. 2(3):233-4. [Medline].

  71. Aberastury MN, Silva WH, Vaccarezza MM, Maxit C, Agosta G. Epilepsia partialis continua associated with levamisole. Pediatr Neurol. 2011 May. 44(5):385-8. [Medline].

  72. Molyneux PD, Barker RA, Thom M, van Paesschen W, Harkness WF, Duncan JS. Successful treatment of intractable epilepsia partialis continua with multiple subpial transections. J Neurol Neurosurg Psychiatry. 1998 Jul. 65(1):137-8. [Medline].

  73. Misawa S, Kuwabara S, Shibuya K, Mamada K, Hattori T. Low-frequency transcranial magnetic stimulation for epilepsia partialis continua due to cortical dysplasia. J Neurol Sci. 2005 Jul 15. 234(1-2):37-9. [Medline].

  74. Morales OG, Henry ME, Nobler MS, Wassermann EM, Lisanby SH. Electroconvulsive therapy and repetitive transcranial magnetic stimulation in children and adolescents: a review and report of two cases of epilepsia partialis continua. Child Adolesc Psychiatr Clin N Am. 2005 Jan. 14(1):193-210, viii-ix. [Medline].

  75. Valentin A, Ughratdar I, Cheserem B, Morris R, Selway R, Alarcon G. Epilepsia partialis continua responsive to neocortical electrical stimulation. Epilepsia. 2015 Aug. 56 (8):e104-9. [Medline].

  76. Rotenberg A, Bae EH, Takeoka M, Tormos JM, Schachter SC, Pascual-Leone A. Repetitive transcranial magnetic stimulation in the treatment of epilepsia partialis continua. Epilepsy Behav. 2009 Jan. 14(1):253-7. [Medline].

  77. Browner N, Azher SN, Jankovic J. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006 Sep. 21(9):1500-2. [Medline].

  78. Saboo AR, Singhi P. HIV infection presenting with stroke and epilepsia partialis continua. Indian Pediatr. 2012 Jul. 49(7):589. [Medline].

  79. Schwab N, Bien CG, Waschbisch A, Becker A, Vince GH, Dornmair K. CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain. 2009 May. 132(Pt 5):1236-46. [Medline].

 
Previous
Next
 
Table. Bancaud Classification
Type 1 ( Classic) Type 2 (Rasmussen)
Rolandic fixed lesion Normal developmental and history until seizure onset
Neurological deficit Preceding partial motor
Preceding partial motor seizures Following myoclonic jerks
Following myoclonic jerks Abnormal EEG background with focal and diffuse paroxysmal abnormalities
Focal abnormalities on EEG Progressive course
Nonprogressive course Intractable epilepsy
Surgery usually effective  
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.